This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This includes beta-blockers, ACEinhibitors, ARBs, ARNIs, MRAs, and SGLT2 inhibitors. The COVID-19 pandemic highlighted the potential of video consults (VCs), even among older patients, to support self-care, improve disease management, and facilitate collaboration with caregivers.
Researchers tracked outcomes for a median of just under 18 months. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin. The study’s primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1% of the control group.
Researchers tracked outcomes for a median of just under 18 months. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin. The study’s primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1% of the control group.
The Patient Health Questionnaire-9, the COVID-19 Stress Scale, the Minnesota Living with HF Questionnaire and the Lebanese Medication Adherence Scale were used to evaluate depression, stress, quality of life and medication adherence, respectively. were on ACEinhibitors/angiotensin receptor blockers and 54.9%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
ACE Inhibitor 
119 
Let's personalize your content